Fortitude Advisory Group L.L.C. Purchases 298 Shares of Eli Lilly and Company (NYSE:LLY)

Fortitude Advisory Group L.L.C. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 14.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,316 shares of the company’s stock after purchasing an additional 298 shares during the quarter. Eli Lilly and Company accounts for approximately 0.8% of Fortitude Advisory Group L.L.C.’s investment portfolio, making the stock its 20th largest holding. Fortitude Advisory Group L.L.C.’s holdings in Eli Lilly and Company were worth $1,350,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company during the third quarter worth $27,000. Legacy Financial Group LLC bought a new stake in Eli Lilly and Company during the third quarter worth $35,000. Optiver Holding B.V. bought a new stake in Eli Lilly and Company during the third quarter worth $36,000. Finally, Family CFO Inc bought a new stake in Eli Lilly and Company during the third quarter worth $40,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 0.6 %

LLY traded down $4.35 during trading on Wednesday, reaching $776.75. 2,762,272 shares of the stock traded hands, compared to its average volume of 3,067,902. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $738.04 billion, a PE ratio of 133.47, a P/E/G ratio of 1.61 and a beta of 0.34. The stock’s 50-day moving average is $761.41 and its 200 day moving average is $669.21. Eli Lilly and Company has a 12 month low of $399.26 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.62 earnings per share. Equities analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on LLY shares. Morgan Stanley upped their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Bank of America upped their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Truist Financial upped their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $742.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.